For example, blocking the CD47-SIRPα pathway together with treatment with sodium stibogluconate (SSG), an antileishmaniasis drug, overcomes the resistance of anti-CD20-opsonized B-cell lymphoma cells to neutrophil killing.341 Hu5F9-G4 (now known as magrolimab) is in a phase II/III clinical study for AML and has shown a favorable safety profile in combination with azathioprine (AZA).342,343 Magrolimab in combination with AZA demonstrated early efficacy in AML patients with mutated TP53.344,345. Here, CD47 is linked to acute myeloid leukemia.